- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04330820
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (RELAX)
Phase-I/II Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- To determine safety, tolerability, maximum tolerated dose, and recommended phase II dose of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy.
- To assess the preliminary efficacy of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive salvage therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Christoph Röllig, Prof. (MD)
- Phone Number: +49 351 458 3775
- Email: christoph.roellig@ukdd.de
Study Contact Backup
- Name: Martin Wermke, MD
- Phone Number: +49 351 7566
- Email: martin.wermke@uniklinikum-dresden.de
Study Locations
-
-
-
Augsburg, Germany, 86156
- Klinikum Augsburg, Medizinische Klinik II
-
Chemnitz, Germany, 09113
- Klinikum Chemnitz, Krankenhaus Küchwald, Klinik für Innere Medizin III
-
Dresden, Germany, 01307
- Universitätsklinikum Dresden, Medizinische Klinik I
-
Essen, Germany, 45122
- Universitätsklinikum Essen; Zentrum für Innere Medizin
-
Frankfurt am Main, Germany, 60590
- Universitätsklinikum Frankfurt am Main, Medizinische Klinik II
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik für Innere Medizin II
-
Marburg, Germany, 35033
- Universitätsklinikum Marburg
-
München, Germany, 80634
- Rotkreuzklinikum München, III. Medizinische Abteilung-Hämatologie und Onkologie
-
Münster, Germany, 48149
- Universitätsklinikum Münster, Medizinische Klinik A
-
Nürnberg, Germany, 90419
- Klinikum Nürnberg Nord, Klinik für Innere Medizin 5
-
Stuttgart, Germany, 70376
- Robert-Bosch-Krankenhaus Hämatologie, Onkologie und Palliativmedizin
-
Würzburg, Germany, 97080
- Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria for both escalation and expansion phase:
- Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained before screening.
- AML according to WHO-2016 criteria, excluding acute promyelocytic leukemia
- Relapsed from first or second CR after 1-2 cycles of standard induction chemotherapy (which must have included cytarabine with an anthracycline or anthracenedione), including relapse after allogeneic stem cell transplantation (dose escalation and expansion part)
- Age 18-75 years
Fit for intensive chemotherapy, defined by
- ECOG 0-2, life expectancy > 3months
Adequate hepatic function: ALAT/ASAT/Bilirubin ≤2.5 x ULN*
- unless considered due to leukemic organ involvement Note: Subjects with Gilbert's Syndrome may have a bilirubin > 2.5 × ULN per discussion between the investigator and Coordinating investigator.
- Adequate renal function assessed by serum creatinine ≤ 1.5x ULN OR creatinine clearance (by Cockcroft Gault formula) ≥ 50 mL/min
- Patient is afebrile and hemodynamically stable for at least 72 hours at the time of study medication initiation.
- Male subjects must agree to refrain from unprotected sex and sperm donation from time point of signing the informed consent until 30 days after the last dose of study drug.
Women must fulfill at least one of the following criteria in order to be eligible for trial inclusion:
- Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml)
- Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days before the first dose of study drug.
- Continuous and correct application of a contraception method with a Pearl Index of <1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD) from time point of signing the informed consent until 30 days after the last dose of study drug.
Note: At present, it is not known whether the effectiveness of hormonal contraceptives is reduced by venetoclax. For this reason, women should use a barrier method in addition to hormonal contraceptive methods.
- Sexual abstinence
- Vasectomy of the sexual partner
Inclusion criteria applying for expansion phase (Phase II) only:
• Primary refractory after 1-2 cycles of standard induction chemotherapy (100 to 200 mg/m2 cytarabine over 7-10 days plus anthracycline or mitoxantrone over 3 days or equivalent treatment, e.g. CPX351) or relapsed from first or second CR after 1-2 cycles of standard induction chemotherapy (which must have included cytarabine with an anthracycline or anthracenedione), including relapse after allogeneic stem cell transplantation
Note: Primary refractory disease is defined by either ≥ 20% myeloid blasts on early response assessment around day 15 after start of the most recent induction, or by ≥ 5% myeloid blasts after blood recovery after start of the most recent induction, respectively.
Exclusion Criteria:
- Acute promyelocytic leukemia (AML M3)
- CNS involvement or subjects with extramedullary disease only
- Known hypersensitivity to excipients of the preparation or any agent given in association with this study including cytarabine or mitoxantrone
- Intended hematopoietic stem cell transplantation planned as early conditioning from aplasia without previous blood count recovery
- Cumulative previous exposure to anthracyclines of >410 mg/m2 doxorubicin equivalents
- Acute GVHD ≥ grade 2, extensive chronic GVHD or requiring systemic immunosuppressive therapy within 2 weeks prior to start of study treatment
- HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections).
- Inability to swallow oral medications
- Any malabsorption condition
- Cardiovascular disability status of New York Heart Association (NYHA) Class ≥ 2.
Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
- Chronic respiratory disease that requires continuous oxygen use.
- White blood cell count > 25 × 109/L. Note: Hydroxyurea is permitted to meet this criterion.
- AML relapse treatment with any investigational or commercial drug within 14 days before enrolment. Hydroxyurea is allowed until enrolment to control peripheral WBC counts. Toxic effects of previous investigational drug treatment have to recover to Grade <2.
- Substance abuse, medical, psychological, or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results
- Acute non-hematologic toxicities from any prior anti-leukemia therapy or from previous investigational drugs that have not resolved to Grade <2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Evens (CTCAE), Version 5.0
- Pregnant or breastfeeding women. Breastfeeding has to be discontinued before onset of and during treatment and should be discontinued for at least 3 months after end of treatment.
- History of active or chronic infectious hepatitis unless serology demonstrates clearance of infection (Occult or prior hepatitis B virus (HBV) infection (defined as negative hepatitis B surface antigen and positive total hepatitis B core antibody) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior but cured hepatitis B are eligible. Patients positive for hepatitis C virus antibody are eligible provided PCR is negative for HCV RNA.)
- History of clinically significant liver cirrhosis (e.g., Child-Pugh class B and C).
- Live-virus vaccines given within 28 days prior to the initiation of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Venetoclax+Cytarabin+ Mitoxantron
The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
|
This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I. The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (= recommended phase II dose) of cytarabine in combination with venetoclax plus mitoxantrone
Time Frame: appr. 9 months
|
number of dose limiting toxicities related to venetoclax per cohort
|
appr. 9 months
|
CR/CRi rate
Time Frame: appr. 12 months
|
preliminary efficacy of venetoclax in combination with increasing cytarabine doses plus fixed dose mitoxantrone
|
appr. 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
remission
Time Frame: appr. 48 months
|
Duration of Remission and Depth of remission (MRD)
|
appr. 48 months
|
Relapse
Time Frame: appr. 48 months
|
Cumulative incidence of relapse
|
appr. 48 months
|
Relapse-free survival
Time Frame: appr. 48 months
|
number of participants alive without relapse
|
appr. 48 months
|
Mortality
Time Frame: appr. 48 months
|
Early mortality (within 14 and 30 days)
|
appr. 48 months
|
Proportion of allogeneic stem cell transplantation
Time Frame: appr. 48 months
|
number of allogeneic stem cell transplantation following response
|
appr. 48 months
|
incidence and severity of adverse Events [safety and tolerability]
Time Frame: appr. 48 months
|
number and grade of Adverse Events assessed by CTCAE v5.0
|
appr. 48 months
|
Overall survival
Time Frame: appr. 48 months
|
number of patients alive
|
appr. 48 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of biomarkers predicting CR/CRi achievement
Time Frame: appr. 48 months
|
Baseline samples from all patients with be sequenced for genes which have been associated with response to venetoclax treatment.
The panel will include TP53, WT1, PDGFRB, ASXL1, and EZH2.
Testing for additional markers may be added triggered by new scientific evidence.
|
appr. 48 months
|
clonal architecture of hematopoiesis
Time Frame: appr. 48 months
|
We will test for changes of the clonal architecture of hematopoiesis during therapy and maintenance treatment.
This will be done by NGS using a gene panel including TP53, DNMT3A, ASXL1, TET2, JAK2, RUNX1, SF3B1, and EZH2.
|
appr. 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christoph Röllig, Prof. (MD), Technische Universität Dresden (TUD)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TUD-RELAX1-070
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Adult AML
-
The First Hospital of Jilin UniversityActive, not recruitingRelapsed Adult AML | Relapsed Adult ALLChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Recruiting
-
Actinium PharmaceuticalsWithdrawnAcute Myeloid Leukemia | Relapsed Adult AML
-
Agios Pharmaceuticals, Inc.Approved for marketingAcute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
-
Actinium PharmaceuticalsRecruitingAcute Myeloid Leukemia | Relapsed Adult AMLUnited States
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Dongguan People's Hospital; Huizhou Municipal Central... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | Refractory Leukemia | Relapsed Adult AMLChina
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Medical College of WisconsinNot yet recruitingRelapsed Adult AML | Refractory AMLUnited States
Clinical Trials on Venetoclax Oral Tablet
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand
-
Pharmacyclics LLC.Janssen Research & Development, LLCActive, not recruitingMantle-Cell LymphomaFrance, Canada, Spain, United States, Hungary, Korea, Republic of, Greece, Australia, Netherlands, Belgium, United Kingdom, Czechia, Germany, Poland, Italy, Turkey, Ukraine
-
Niguarda HospitalRecruitingCLL TransformationItaly, Switzerland
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruiting
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States